Literature DB >> 18317009

Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study.

Samir K Gupta1, Raymond M Johnson, Chandan Saha, Kieren J Mather, Martha L Greenwald, Jeffrey S Waltz, Jalees Rehman, Michael P Dubé.   

Abstract

We hypothesized that heightened systemic inflammation contributes to the increased rate of cardiovascular events in HIV-infected patients not receiving combination antiretroviral therapy. We performed a pilot trial to assess the effects of the nuclear factor-kappaB inhibitor salsalate on flow-mediated dilation of the brachial artery, a measure of endothelial function. Flow-mediated dilation significantly improved after 8 weeks of salsalate. However, hepatotoxicity occurred frequently. Research using alternative agents is warranted to examine the role of inflammation in HIV-related cardiovascular disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18317009     DOI： 10.1097/QAD.0b013e3282f470d2

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  16 in total

Review 1.  Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.

Authors:  Cyrus DeSouza; Vivian Fonseca
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

Review 2.  Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

Authors:  Allison B Goldfine; Steven E Shoelson
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

Review 3.  Inflammation, immune activation, and cardiovascular disease in HIV.

Authors:  Eric Nou; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

4.  Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects.

Authors:  Michael P Dubé; Changyu Shen; Kieren J Mather; Jeff Waltz; Martha Greenwald; Samir K Gupta
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

5.  Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation.

Authors:  Linden Ann Green; Chul Kim; Samir K Gupta; Gangaraju Rajashekhar; Jalees Rehman; Matthias Clauss
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

6.  Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.

Authors:  Gary L Pierce; Lisa A Lesniewski; Brooke R Lawson; Stacy D Beske; Douglas R Seals
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 7.  Immune activation and cardiovascular disease in chronic HIV infection.

Authors:  Chris T Longenecker; Claire Sullivan; Jason V Baker
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 8.  The vascular endothelium in diabetes--a therapeutic target?

Authors:  Kieren J Mather
Journal:  Rev Endocr Metab Disord       Date:  2013-03       Impact factor: 6.514

9.  No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.

Authors:  Michael P Dubé; Changyu Shen; Martha Greenwald; Kieren J Mather
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

10.  Prevention of age-related endothelial dysfunction by habitual aerobic exercise in healthy humans: possible role of nuclear factor κB.

Authors:  Ashley E Walker; Rachelle E Kaplon; Gary L Pierce; Molly J Nowlan; Douglas R Seals
Journal:  Clin Sci (Lond)       Date:  2014-12       Impact factor: 6.124
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.